March 25, 2022 -- KSQ Therapeutics will give an oral presentation at the upcoming American Association for Cancer Research (AACR) 2022 annual meeting, held April 8-13.
The company will provide an overview of preclinical data on KSQ-4279, its USP1 inhibitor, as part of the ongoing phase I clinical trial of KSQ-4279 in advanced solid tumors.
USP1 was identified by KSQ's CRISPRomics platform as a novel synthetic lethal target in cancers with certain types of genomic instability, the company said.
The company's presentation will be on April 12 at 1:05-1:20 p.m. CT.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
